Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colloidal silver versus saline plus antibiotic for recalcitrant chronic rhinosinusitis
ACTRN12616001558415Phase 2Completed
- Sponsor
- The Queen Elizabeth Hospital
- Start
- Nov 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, double-blind trial of silver nanoparticles, amoxicillin + clavulanate and clarithromycin in chronic rhinosinusitis (CRS) (2 arms), sponsored by The Queen Elizabeth Hospital. Primary endpoint: Presence or absence of bacterial growth on sinonasal culture. Started Nov 2016; status: completed.
02
Drugs
silver nanoparticlesamoxicillin + clavulanateclarithromycin
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on ACTRN12616001558415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001558415.